Nezam El-Tayebat Fact CheckA scientific assessment of the “نظام الطيبات” nutrition system
Choose country

False Certainty of evidence: moderate provisional C-CAN-04

Cancer will respond to the Tayebat system; a patient with a malignant tumour should start the system now (diet as cancer treatment).

Safety note: Do not refuse, stop or delay recommended cancer treatment (surgery, chemotherapy, radiotherapy, hormone or targeted therapy) in favour of a diet. In curable cancers, replacing standard treatment with alternative approaches is associated with a markedly higher risk of death (I-CHM-03, I-CHM-04), and even four-week delays are associated with higher mortality (I-CHM-07). Late effects are real and are managed by survivorship and cardio-oncology care; discuss them with the treating oncology team. Nutrition can be adapted alongside treatment with the oncology team. No individual medical advice is given here.
Conclusion: There is no evidence that the Tayebat diet treats cancer; using it instead of treatment is dangerous.
  1. Original statement
  2. Scientific assessment
  3. In plain language
  4. Studies on this claim
  5. Regional context
  6. What applies in my country?
  7. References

Original statement

زي ما انا اكتشفت ان السرطان هيستجيب لي شغلي اه هيستجيب لي شغلي طبعا

verbatim according to source. Translation by the project; the Arabic wording is authoritative.

Translation

Cancer will respond to the Tayebat system; a patient with a malignant tumour should start the system now (diet as cancer treatment).

Origin

Source status
Video transcript (own words)
Attribution
Elawady (machine transcript)
Video
السرطان ١ (Open source)
Published
26 January 2025
Timestamp
0:44:36 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
Attribution uncertainty
Archive transcript (YouTube CC or AI-generated); no timestamps; spelling errors of the machine transcript are kept verbatim; wording may deviate from the spoken words.
Population concerned

Cancer patients

Geographic restriction by Elawady

none found

Diverging source versions

ايوه طبعا يمشي على النظام اللي عنده ورم خبيث ده يمشي على النظام من دلوقتي

Source status
Video transcript (own words)
Attribution
Elawady (machine transcript)
Video
السرطان ١ (Open source)
Published
26 January 2025
Timestamp
0:19:06 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)

خفف سرطانات خفف

Source status
Video transcript (own words)
Attribution
Elawady (machine transcript)
Video
Dr.D Clinics - Diaa Al Awady is live! مقدمة عن الدهون ⧸ الغشاء الخلوي (Open source)
Published
9 April 2025
Timestamp
not available (transcript has no timings)

تنبيه: لا يُعد هذا دليلاً لعلاج السرطان. المرضى تحت إشراف فريق أورام.

Source status
Third-party site (unofficial)
Attribution
Third-party site (unofficial)
Origin
https://mytayibat.com/mytayibat-cancer

ايه النظام المناسب للقضاء على سرطان المخ يا باشا هو نظام واحد انا ما اخترعتش 600 نظام [أصوات شخير] يعني انا ما اخترعتش 600 نظام هو نظام واحد هو نظام الطيبات اا ونظام الطيبات هو مش نظام بمعنى اصح هو تكنيك وانا اسف كلمه تكنيك دي لو

Asked which system is suitable for eliminating brain cancer, he answered that there is only one system, the Tayebat system, which is a technique based on forbidding some foods and allowing others.

Source status
Video transcript (own words)
Attribution
Elawady (machine transcript)
Video
بدأت قناة ＂Dr Diaa Al Awady د ضياء العوضي＂ بثًا مباشرًا تصليح مفاهيم (Open source)
Published
31 March 2026
Timestamp
0:13:42 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
Attribution uncertainty
Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.

Scientific assessment

False – The statement contradicts the robust evidence.

Certainty of evidence: moderate – Further research may still affect the assessment.

1. What was claimed?

The diet treats or controls cancer.

2. What is demonstrably correct?

Nutrition matters during cancer (e.g., preventing malnutrition) and healthy weight lowers some cancer risks; using a diet alongside treatment is not by itself harmful (I-CHM-04 shows risk was mediated by refusal).

3. What is wrong or exaggerated?

No evidence that the Tayebat diet shrinks or cures cancer; testimonies in the videos are unverifiable and often involve prior surgery or chemotherapy. Alternative-only management of curable cancers was associated with HR 2.50 for death (I-CHM-03). In patients who were eventually treated, each 4-week delay within the studied range of about 4-16 weeks was associated with 6-13% higher mortality for many indications (observational; I-CHM-07); the longer delays of trying a diet first were not studied, and the authors warn against extrapolating beyond 16 weeks.

4. What remains unclear?

Long-term outcomes of the patients presented in the videos.

5. Which studies support it?

None.

6. Which studies contradict it?

I-CHM-03, I-CHM-04, I-CHM-07.

7. What applies to Germany and Europe?

Not region-specific; the evidence on the harms of replacing or delaying cancer treatment (I-CHM-03, I-CHM-04, I-CHM-07) applies equally in Germany and Europe.

8. What is known about Egypt?

Not region-specific; the same risks apply. The videos address mainly Egyptian and Arab patients, so the claim is practically relevant there.

9. What practical conclusion is appropriate?

A diet may be discussed as supportive care with the oncology team, never as a replacement.

Assessment details

Rationale for certainty of evidence

No clinical study of the Tayebat system in cancer exists (none found); indirect but consistent evidence shows excess mortality when diet/alternative approaches replace treatment. Certainty is moderate because the evidence on this specific diet is indirect.

Source quality

Machine transcript; third-party site disagrees.

Regional transferability

High.

Regional scope of the claim
general (biological/medical)
Last reviewed
25 October 2026 provisional

In plain language

Dr. Diaa said that cancer 'will respond' to his system and that a patient with a malignant tumour should start it immediately. There is no study showing that this diet treats cancer. Studies show that people who use alternatives instead of standard treatment die more often. Eating well can support patients, but only together with proper cancer treatment.

Studies on this claim

Studies supporting the claim (0)

No studies in this group.

Studies contradicting or limiting the claim (3)

  • Patients who used only alternative medicine for curable cancer died more often

    Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145
    Cohort studyindependent cross-checkabstract only checked★ key study

    Risk of death was 2.5 times higher overall and 5.7 times higher for breast cancer.

    Alternative-only approach worse

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Compare AM-only vs conventional treatment.

    How was the study done?

    Matched registry cohort.

    How many people, animals or samples were studied?

    840 matched patients.

    What was actually found?

    HR 2.50 for death.

    How large was the observed effect?

    HR 5.68 breast cancer.

    What do the results mean in everyday life?

    Replacing cancer treatment with alternatives is dangerous.

    What are the study's limitations?

    Observational.

    What does it say about Elawady's specific claim?

    Contradicts refusing therapy.

    Do the results apply to Germany and Europe?

    Moderate.

    What can explicitly not be concluded from this study?

    Effects of complementary approaches used alongside treatment.

    Scientific details →

  • Refusing standard cancer treatment, not complementary medicine itself, raised the risk of death

    Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487
    Cohort studyindependent cross-checkabstract only checked★ key study

    Users of complementary medicine refused chemotherapy or radiotherapy far more often and had about twice the risk of death.

    Risk mediated by refusing therapy

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Study CM and survival.

    How was the study done?

    Registry cohort.

    How many people, animals or samples were studied?

    258 vs 1,032.

    What was actually found?

    HR 2.08; explained by refusal.

    How large was the observed effect?

    5-y OS 82.2% vs 86.6%.

    What do the results mean in everyday life?

    Diet or other approaches alongside treatment are not the problem; replacing treatment is.

    What are the study's limitations?

    Observational.

    What does it say about Elawady's specific claim?

    Contradicts refusal advice.

    Do the results apply to Germany and Europe?

    Moderate.

    What can explicitly not be concluded from this study?

    Causal effect of any single CM.

    Scientific details →

  • Each month of delay in cancer treatment raises the risk of death

    Hanna TP et al.. BMJ 2020 · PMID 33148535 · DOI 10.1136/bmj.m4087
    Meta-analysisindependent cross-checkfull text checked★ key study

    For example, every 4-week delay of breast surgery was linked to 8% higher mortality.

    Trying diet first delays treatment

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Quantify harm from delay.

    How was the study done?

    Meta-analysis.

    How many people, animals or samples were studied?

    1.27 million patients.

    What was actually found?

    Higher mortality with delay.

    How large was the observed effect?

    HR 1.06-1.08 per 4 weeks (surgery).

    What do the results mean in everyday life?

    Do not postpone recommended treatment.

    What are the study's limitations?

    Observational, mostly US registry data; valid only for delays of about 4-16 weeks; not suitable for predicting an individual's risk.

    What does it say about Elawady's specific claim?

    Safety.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    The effect of delays longer than 16 weeks or of refusing treatment altogether; the effect for every cancer type; proof of causation.

    Scientific details →

Studies with mixed or unclear results (0)

No studies in this group.

Regional context

Germany / EU

Not region-specific; the evidence on the harms of replacing or delaying cancer treatment (I-CHM-03, I-CHM-04, I-CHM-07) applies equally in Germany and Europe.

Egypt

Not region-specific; the same risks apply. The videos address mainly Egyptian and Arab patients, so the claim is practically relevant there.

What applies in my country?

General scientific assessment

False There is no evidence that the Tayebat diet treats cancer; using it instead of treatment is dangerous.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

  1. Use of Alternative Medicine for Cancer and Its Impact on Survival.. Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145
  2. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers.. Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487
  3. Mortality due to cancer treatment delay: systematic review and meta-analysis.. Hanna TP et al.. BMJ 2020 · PMID 33148535 · DOI 10.1136/bmj.m4087

← Back to overview